Lonza Group Investor Presentation — July 2024

Document content

Enabling a Healthier World

Half-Year Results 2024

Wolfgang Wienand , CEO

Philippe Deecke, CFO

Lonza Half -Year Results 2024Wolfgang Wienand Joins Lonza as CEO

2−CEO since 1 July 2024

−Previously CEO of the Swiss CDMO Siegfried, SIX: SFZN (since 2019, from 2010

first Chief Scientific Officer, then Chief Strategy Officer), before at Evonik

−Almost two decades of experience in the biopharma CDMO industry in General

Management, Strategy, Business Development, Innovation, R&D

−Working closely with the Executive Committee and the Board of Directors with a

focus on priorities on execution and foundations for long -term success

−Performance well on track to deliver Full -Year Outlook: Sales of CHF 3.1 billion

and 1.8% CER sales growth

−CHF 893 million CORE EBITDA resulted in a margin of 29.2%

−Robust performance in CDMO business, with headwinds in the capsules

business within the Capsules & Health Ingredients (CHI) division

−Solid free cash flow at CHF 296 million

−Group Outlook 2024 confirmed: flat CER sales growth and CORE EBITDA margin

−Mid-Term Guidance 2024

2028, upgraded in March, confirmedExecutive Summary1

1CORE results and Constant Exchange Rates (CER) are non -IFRS measures.

For Lonza's definition of CORE results, also refer to the Alternative Performance Measures Brochure published in conjunction with the Lonza Half -Year Report.H1 Commercial Highlights

−Healthy levels of new contract CDMO signings in H1 2024

−Encouraging early phase enquiries for CDMO business

−Cell & Gene Technologies signed a multi -year commercial supply agreement

with a major customer

−Multiple signings for Synaffix linker technologiesPipeline Momentum

Selected SigningsLonza Half -Year Results 2024Acquisition of Genentech Vacaville (US) Site from Roche

−Acquisition extends high -quality manufacturing

Preview truncated — download the full document for the complete content.